Key result
Continuous-flow ventricular assist devices are associated with significant hematologic changes, including the loss of large von Willebrand factor multimers, which may contribute to bleeding.
Understanding the hematologic effects of continuous-flow VADs, such as acquired von Willebrand disease, is critical to managing bleeding and thrombosis complications in heart failure patients.
Answers are grounded in this paper and cite their sources.
May warrant heightened bleeding surveillance in continuous-flow VAD recipients; leaves open optimal antithrombotic strategies for future trials.
B ecause of the obligate intravascular location of contem- porary continuous-flow ventricular assist devices (CF-VADs), it is not surprising that bleeding and thrombosis are among the most common and feared complications of this therapy, respectively.Although strides have been made in our understanding of the pathophysiology of continuous flow, intravascular CF-VADs have been widely used only in the last few years, and a great deal remains less well known (or unknown).Outcomes have improved significantly over the past decade, but a deeper understanding of how these devices perturb the delicate intrinsic balance of bleeding and thrombosis is critical to guide therapy and to overcome the current obstacles to achieving a long-term safety profile comparable to that of mechanical prosthetic valves. Pathophysiology Hematologic Effect of CF-VADsThe hematologic effects of CF-VADs are of significant interest and importance and have recently been reviewed in detail elsewhere.1,2 Hemocompatibility refers to the interaction of prosthetic material with blood and can be measured in terms of impact on hematologic, inflammatory, or immunologic parameters, which has been observed clinically as significant and prolonged activation of endothelial and coagulation systems after CF-VAD implantation, including intercellular adhesion molecule, E-selectin, and tissue factor, for example.3 Hemocompatibility has always been a goal in pump design, along with efforts to maximize blood flow without clinically significant hemolysis, areas of stasis, turbulent flow, or retrograde flow.It has been suggested that the major complications of thrombosis, bleeding, and infection could be related to the effects of blood interaction with the VAD surface, 4,5 and further optimization of surface coatings presents an appealing strategy for additional exploration.6 A better understanding of the impact of blood-VAD surface interactions with the presently used CF-VAD devices, however, is essential to evaluating the impact of novel designs or materials.A few recent observations have provided some insight into the impact of CF-VAD on the hematologic system.The 2 areas with the most data available are acquired von Willebrand disease and platelet activation.We also comment on preliminary findings on the potential role of microparticles. von Willebrand FactorThe finding that has garnered the most attention is the loss of large von Willebrand factor (vWF) multimers, much like Heyde syndrome as described in patients with critical aortic stenosis.7 High shear stress has previously been noted to alter the 3-dimensional structure and to enhance proteolysis of the vWF by ADAMTS-13, 8 -10 a plausible mechanism in the setting of increased shear stress with CF-VADs (see Figure 1A).Veyradier et al 12 noted a high rate of von Willebrand disease in patients with bleeding angiodysplasia without a VAD and proposed that this deficiency was particularly pertinent at the very high shear conditions related to these malformations.In sharp contrast to heart transplant recipients, Geisen et al 13 first reported loss of large vWF multimers in patients supported with HeartMate II and pulsatile VADs despite amounts of vWF antigen that were comparable to that seen in heart transplant recipients (Figure 1B).Impaired collagen binding capacity and ristocetin cofactor activity, a measure of vWF factor binding to platelets, were also lower in all VAD patients.This finding has been confirmed by other groups, 11,14,15 observed to occur within the first few days after left VAD (LVAD) implantation, 16 and noted to resolve after LVAD explantation.17 In contrast to the initial report, 13 others have found altered vWF multimers in CF-VADs but not pulsatile VADs, 18 and altered vWF multimers have been documented after exchange from pulsatile VAD to CF-VAD.19 A small study of CardioWest total artificial heart implants did not find evidence of decreased large vWF multimers in the first year after implantation, 20 but we are unaware of data after prolonged (Ͼ1 year) support or with AbioCor total artificial heart.Taken together, the flow characteristics of a CF-VAD may be a critical factor, but limited and conflicting data on the impact of pulsatile-flow devices suggest that additional factors may be operative.Patients with blood type O have been noted to have lower baseline levels of vWF compared with other blood groups, and 1 study found evidence of frequent bleeding in patients with blood group O. 11 A similar rate was noted in patients with groups B and AB, and a study of coronary artery bypass patients did not
No takes yet. Share an insight, caveat, or question.
Eckman et al. (2012) conducted a review in Patients with continuous-flow ventricular assist devices (CF-VADs). Continuous-flow ventricular assist devices (CF-VADs) was evaluated. Continuous-flow ventricular assist devices are associated with significant hematologic changes, including the loss of large von Willebrand factor multimers, which may contribute to bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: